Previously, Dr. Elder and his colleagues used comparative modeling of FIV and HIV aspartyl proteinases (PRs) to identify specific amino acid residues that interact with the substrate binding pocket in a unique fashion in each protease. They have discovered that HIV protease and FIV protease are very similar structurally but that each has certain unique characteristics which result in strongly preferential homologous gag substrate cleavage. The hypothesis behind the proposed work is that an in-depth understanding of both the similarities and the differences between two distantly related lentiviral proteases will promote development of protease inhibitors that may be efficacious against both FIV and HIV proteases but at that same time, relatively homologous resistance-proof. To explore this hypothesis, Dr. Elder and his colleagues will focus on substrate binding pocket interactions. They will use site-directed mutagenesis to replace FIV-specific residues with HIV-specific residues, both alone and in combinations predicted to be interactive in the three-dimensional structure. Mutant proteases will be expressed in bacteria, purified, refolded. These mutant proteases will be biochemically defined as to their substrate specificities using both natural and synthetic peptide substrates and as to the kinetics of their inhibition by a panel of previously defined HIV protease inhibitors. Interesting mutants will be placed in the context of infectious virus, and examined in cell culture for their potential to be inhibited by, or develop resistance to, known protease inhibitors during virus passage. Where appropriate, the three-dimensional structure of interesting mutant proteases can be examined by Dr. Alex Wlodawer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040882-03
Application #
2871551
Study Section
AIDS and Related Research Study Section 3 (ARRC)
Program Officer
Sarver, Nava
Project Start
1997-02-01
Project End
2001-01-31
Budget Start
1999-02-01
Budget End
2000-01-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Elder, John H; Lin, Ying-Chuan; Fink, Elizabeth et al. (2010) Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res 8:73-80
Elder, John H; Lin, Ying-Chuan; Fink, Elizabeth et al. (2010) Feline Immunodeficiency Virus (FIV) as A Model for Study of Lentivirus Infections: Parallels with HIV. Curr HIV Res :
Chang, Max W; Giffin, Michael J; Muller, Rolf et al. (2010) Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J 429:527-32
Chang, Max W; Ayeni, Christian; Breuer, Sebastian et al. (2010) Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One 5:e11955
Elder, John H; Sundstrom, Magnus; de Rozieres, Sohela et al. (2008) Molecular mechanisms of FIV infection. Vet Immunol Immunopathol 123:3-13
Sundstrom, Magnus; Chatterji, Udayan; Schaffer, Lana et al. (2008) Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology 371:394-404
Heaslet, Holly; Rosenfeld, Robin; Giffin, Mike et al. (2007) Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr 63:866-75
Heaslet, Holly; Lin, Ying-Chuan; Tam, Karen et al. (2007) Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Retrovirology 4:1
Heaslet, Holly; Kutilek, Victoria; Morris, Garrett M et al. (2006) Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. J Mol Biol 356:967-81
Swan, C H; Torbett, B E (2006) Can gene delivery close the door to HIV-1 entry after escape? J Med Primatol 35:236-47

Showing the most recent 10 out of 22 publications